- Home
- CAPR vs ASIX Comparison
CAPR vs ASIX Comparison
Compare CAPR & ASIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- ASIX
- Stock Information
- Founded
- CAPR 2005
- ASIX 2016
- Country
- CAPR United States
- ASIX United States
- Employees
- CAPR N/A
- ASIX N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- ASIX Major Chemicals
- Sector
- CAPR Health Care
- ASIX Industrials
- Exchange
- CAPR Nasdaq
- ASIX Nasdaq
- Market Cap
- CAPR 525.3M
- ASIX 663.1M
- IPO Year
- CAPR N/A
- ASIX N/A
- Fundamental
- Price
- CAPR $9.48
- ASIX $22.42
- Analyst Decision
- CAPR Strong Buy
- ASIX Strong Buy
- Analyst Count
- CAPR 7
- ASIX 2
- Target Price
- CAPR $39.29
- ASIX $37.50
- AVG Volume (30 Days)
- CAPR 1.5M
- ASIX 156.2K
- Earning Date
- CAPR 03-19-2025
- ASIX 05-02-2025
- Dividend Yield
- CAPR N/A
- ASIX 2.85%
- EPS Growth
- CAPR N/A
- ASIX N/A
- EPS
- CAPR N/A
- ASIX 1.62
- Revenue
- CAPR $22,270,465.00
- ASIX $1,517,557,000.00
- Revenue This Year
- CAPR $34.33
- ASIX $6.16
- Revenue Next Year
- CAPR $246.72
- ASIX $6.27
- P/E Ratio
- CAPR N/A
- ASIX $13.84
- Revenue Growth
- CAPR N/A
- ASIX N/A
- 52 Week Low
- CAPR $3.52
- ASIX $20.86
- 52 Week High
- CAPR $23.40
- ASIX $33.00
- Technical
- Relative Strength Index (RSI)
- CAPR 33.11
- ASIX 27.11
- Support Level
- CAPR $12.64
- ASIX $22.45
- Resistance Level
- CAPR $13.81
- ASIX $23.16
- Average True Range (ATR)
- CAPR 1.18
- ASIX 0.64
- MACD
- CAPR -0.32
- ASIX 0.07
- Stochastic Oscillator
- CAPR 9.83
- ASIX 21.03
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About ASIX AdvanSix Inc.
AdvanSix Inc. is a diversified chemistry company playing a critical role in globally supply chains, innovating and delivering essential products for customers in a wide variety of end markets and applications that touch people's lives, such as building and construction, fertilizers, agrochemicals, plastics, solvents, packaging, paints, coatings, adhesives and electronics. The company key products includes: Nylon, Caprolactam, Plant Nutrients, and Chemical Intermediates The majority of sales is from Plant Nutrients products.